China Biologic Products Holdings Inc

China Biologic Products — Investor Presentation (May 2009)

29 slides from China Biologic Products's investor presentation, May 18, 2009

  1. Slide 1: China Biologic Products, Inc.

    May 2009 » China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

  2. Slide 2: Safe Harbor Statement

    @ Safe Harbor Statement CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation includes or incorporates by reference statements that constitute forward- looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securit

  3. Slide 3: Market Capitalization and Key Metrics

    Market Capitalization: $85.6M Revenues (ttm): $60.1M Wtd Avg Diluted Shares as of 03/31/09 21.4M | PIE (ttm) 6.AX | - Net Income 2009E: $18 -$22M | A China Biologic Products, Inc. 5

  4. Slide 4: Company Overview

    @ Company Overview Largest non-state owned plasma-based biopharmaceutical company in China + Fully integrated biologic products company with plasma collection, production and manufacturing research and development, and commercial operations + Through recent equity investments in two government appro

  5. Slide 5: Plasma-Derived Therapeutics

    @Plasma-Derived Therapeutics China Biologic is a fully-integrated plasma-based biopharmaceutical company Manufacturing Fractionation) Plasma Collection Distribution mat 7 a om 7 7 Sonera pioeare Plasma-derived products nors (paid an average ayers Hen pices ma with different applications US$30) visit

  6. Slide 6: Investment Highlights

    Investment Highlights Blood products cannot be substituted in many applications including medical emergencies, and prevention & treatment for some specific diseases such as hepatitis, rabies, tetanus, etc. 0 Revenue USD in Multiple growth drivers including: + Rising demand for plasma-based products

  7. Slide 7: Growing Market Opportunity

    Growing Market Opportunity « Growth of the market for plasma based products in China has accelerated in ao Fapaeerneliaey om recent years its = « Spending on healthcare in China 500 20% continues to increase both in terms of S inn annual spending and as a percentage of =, ne GDP 100 6 + Chinese spen

  8. Slide 8: Plasma Collection

    Plasma Collection - Shandong. Taibang 2008 Total Collected Volume of Plasma in China has Declined Rapidly Due to Government Reform of Industry 5000 (Tons) Collected Plasma in China Except Shandong Taibang 97.0% Collected Plasma by Shandong Taibang Shandong T: age plasma stations: 3 2700 (Tons) Colle

  9. Slide 9: Attractive Acquisitions

    ® Attractive Acquisitions CBPO Completed Acquisitions Estimated Plasma-Based Products Market Share in China Cee Biologic Technologies Blood Products ‘Acquired 90% controlling interest in Acquired 35% equity interest in Xian ‘Chongging Dalin Biologic ‘Huitian Blood Products Technologies, which owns 5

  10. Slide 10: Existing Operations

    Existing [| Dalin) Plasma collection centers in operation u Estimated annual plasma collection volume (tons) Plasma manufacturing facilities Plasma manufacturing capacity (tons) (1) China Biplogic agguired 90% controlling interest in Chongqing Dalin Biologic Technologies, which (1D ibe'an efcclive S

  11. Slide 11: Plasma Market: China vs. Developed Nations

    Region China* More developed countries” Region China More developed countries * Per million population Plasma Market: China vs. Developed Nations IVIG (Intravenous Albumin Immunoglobulin G) 100kg ‘4kg 200-300kg 10kg Range of Plasma Products Used Number of Human Various types of Plasma Products __Alb

  12. Slide 12: Mandates Strengthen Market Structure and Drive Consolidation

    ndates Strengthen Market Ss ture/Drive Consolidation Government Reform of Plasma-based Industry ~ Reform of blood collection stations in 2006 + GMP Certification required for blood collection stations, biopharmaceutical manufacturers + Restriction of imported products due to past outbreaks + Limited

  13. Slide 13: Product Revenue Mix

    @ @Product Revenue Mix _—— Increasing product diversification and growth in high margin specialty products Three new products currently in cl cal trials PRODUCTS % of Q1 2009 Sales'")| % of Q1 2008 Sales 58.4% 58.1% 0.3% 2.9% Human Immunoglobulin for Intravenous Injection 25.4% 21.1% 11% 15.3% Human

  14. Slide 14: Focus on R&D

    Focus on R&D On-going R&D Objectives + Expand portfolio of plasma-based biopharmaceutical products «+ Maximize manufacturing efficiency and safety « Promote product safety through implementation of new technologies + Refine production technology on existing products China Biologic Products, Inc. & :

  15. Slide 15: New Product Pipeline

    @New Product Pipeline Human Hepatitis B Immunoglobulin (pH 4) for Intravenous Injection Human Prothrombin Complex Concentrate Human Coagulation Factor Vill Human Fibrinogen Human Immunoglobulin for Intravenous Injection - 10% Approved to commence clinical trial (stage 8) Commercial Production expect

  16. Slide 16: New Product Approval Process

    @New)Product Approval Process S — a Overview of SFDA Approval Process for New Plasma Products 1 Planning stage 1 2 Feasibility study and assumption clarification 2 3 Develop scope and technique for testing the new medicine 6 “4 Preparation of a virus inactivation report and submission to the NIGPBP

  17. Slide 17: GMP Certification

    GMP Certification + Shandong Taibang’s GMP certification was renewed in August 2008, it is the first company aaa in the industry to pass the new version of GMP 2.RGMPIES inspection ae + GMP certification is granted by the SFDA and “ oi assures the quality, safety, and effectiveness of pharmaceutical

  18. Slide 18: Stringent Quality Control

    ® Gtringent Quality Control + One of first plasma-based manufacturers in China to receive GMP certification (1999); renewed in 2008 + Awarded Advanced High-tech Enterprise Certification by Ministry of Science and Technology of PRC (2006) ‘+ Accepted into Double Hundred Project by Shandong Economic a

  19. Slide 19: Management Profiles

    Management Profiles Chao Ming Zhao, CEO of China Biologic Products + Chief Financial Officer of China operating subsidiary between September 2003 and May 2008 + Over 10 years of experience in finance, accounting and intemal control + Certified Accountant in the PRC and an international registered in

  20. Slide 20: A profitable, rapidly growing plasma-based biopharmaceutical products company in China

    & China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China

  21. Slide 21: Strong Revenue Growth

    ng Revenue Growth Revenue US $ in Millions 90. 100 aa 324 22 “ot | 100 oo | 2006 2007 Guidance 2009: ' 2009 Full Year Range of Revenue : $90 to $100 million 2009 Full Year Range of Net Income : $18 to $22 mi China Biologic Products, Inc. a

  22. Slide 22: Attractive Gross Margin

    ®Attractive Gross Margin os = = 300 200 09 , ere .

  23. Slide 23: Earnings per Share

    2007 402008 102008 $0.10 $0.20 1 ‘based on the current share count China Biologic Products, Inc. a

  24. Slide 24: Income Statement

    come Statement (Sin million) 2009 2008 2008 2007 2008 Gross Profit $14.9 $5.9 $327 $22.5 $126 ‘Operating Income $10.1 $3.6 $20.3 $128 $6.2 Net income $4.3 $23 $120 $8.2 $3.8 sola Ral lle 21,434,942 21,964,168 21,856,342 21,861,014 21,434,942 & 24

  25. Slide 25: Balance Sheet

    Cash and cash equivalents 340 as Total Current Assets 65. 252 Total Current Liabilities 63.0 189 Total Shareholders’ Equity* 399 a2 “Excludes Non-controling interest Biologie Products, Inc. 25

  26. Slide 26: Peer Valuation

    Peer Valuation Revenue EW StockPrice 2008 ‘Company Ticker grziz00e) Revenues «TOWN «ZOOBEPS PIE EBITDA Hualan Biological Engineeragine, 00200782 $3.90 $69.8 m 35.3% $0.13 30.0 313 Beijing Tiantan Biological Products 600161.ss $2.97 $98.9 m 28.2% $0.04 743 253 Corp. Ltd. Unisplendour Guhan Giaip 0005

  27. Slide 27: Investment Highlights Summary

    dnvestment Highlights Summary a — Largest non-state owned, fully-integrated producer of plasma-based biopharmaceutical company in China Rapidly growing demand for plasma-based products Under penetrated, consolidating market Securing raw materials supply High barriers to entry with strict regulatory

  28. Slide 28: Contact

    Contact China Biologic Products Inc. CCG Investor Relations Inc. Y. Tristan Kuo Crocker Coulson, President No.14 East Hushan Road 1325 Avenue of the Americas, Suite 2800 Taian City, Shandong 271000 New York, NY 10019 PRC Tel: 1 (646) 213-1915 Tel: 86 538-6202306 Crocker.Coulson@ccgir.com IR@chinabio

  29. Slide 29: China Biologic Products, Inc.

    May 2009 o, China Biologic Products, Inc. A profitable, rapidly growing plasma-based biopharmaceutical products company in China >

China Biologic Products — Investor Presentation (May 2009) on 6ix